Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 20/20 | 0.79 |
| ▸ | MMP13 | P45452 | 20/20 | 0.79 |
| ▸ | MMP2 | P08253 | 1/20 | 0.79 |
| ▸ | MMP3 | P08254 | 1/20 | 0.79 |
| ▸ | MMP9 | P14780 | 1/20 | 0.79 |
| ▸ | MMP8 | P22894 | 1/20 | 0.79 |
| ▸ | MMP12 | P39900 | 1/20 | 0.79 |
| ▸ | MMP14 | P50281 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydroxyamine SCHEMBL5914587 | 0.98 | MMP1 (0.76) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL1080224 | 0.93 | MMP1 (0.80) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL12076481 | 0.93 | MMP1 (0.80) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL7208011 | 0.93 | MMP1 (0.80) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL27415619 | 0.91 | MMP1 (0.76) | MMP1MMP13MMP2MMP3MMP9 | |
| Hydroxyamine SCHEMBL5139159 | 0.91 | MMP1 (0.77) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL7978660 | 0.89 | MMP1 (0.77) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL6869740 | 0.89 | MMP1 (0.77) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL25304 | 0.88 | MMP1 (1.00) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL12076423 | 0.88 | MMP1 (0.79) | MMP1MMP13MMP2MMP3MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2734205-A1 | HETEROCYCLIC PROTEIN KINASE INHIBITORS | Tolero Pharmaceuticals, Inc. (US) | 2014-05-28 | — | — | EP | disclosed |
| EP-2646054-A1 | METHODS FOR TREATING A TUMOR USING AN ANTIBODY THAT SPECIFICALLY BINDS GRP94 | University of Pittsburgh - Of the Commonwealth System of Higher Education (US) | 2013-10-09 | — | — | EP | disclosed |
| WO-2013013188-A1 | HETEROCYCLIC PROTEIN KINASE INHIBITORS | TOLERO PHARMACEUTICALS, INC. (US) | 2013-01-24 | — | — | WO | disclosed |
| EP-1773836-B1 | PYRROLOPYRIMIDINE DERIVATIVES USEFUL IN CANCER TREATMENT | PFIZER PROD INC (US) | 2012-09-05 | — | — | EP | disclosed |
| WO-2012075324-A1 | METHODS FOR TREATING A TUMOR USING AN ANTIBODY THAT SPECIFICALLY BINDS HMW-MAA | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2012-06-07 | — | — | WO | disclosed |
| WO-2012075327-A1 | METHODS FOR TREATING A TUMOR USING AN ANTIBODY THAT SPECIFICALLY BINDS GRP94 | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2012-06-07 | — | — | WO | disclosed |
| EP-2018383-B1 | TRIAZOLOPYRAZINE DERIVATIVES USEFUL AS ANTI-CANCER AGENTS | PFIZER PROD INC (US) | 2011-11-09 | — | — | EP | disclosed |
| US-20050075340-A1 | Triazolotriazine compounds and uses thereof | SUGEN, INC. | 2005-04-07 | — | — | US | disclosed |
| WO-2004106319-A1 | CRYSTAL FORMS OF 4-[4-(4-FLUOROPHENOXY)BENZENESULFONYLAMINO]-TETRAHYDROPYRAN-4-CARBOXYLIC ACID HYDROXYAMIDE | PFIZER PRODUCTS INC. (US) | 2004-12-09 | — | — | WO | disclosed |
| EP-1070058-B1 | (4-ARYLSULFONYLAMINO)-TETRAHYDROPYRAN-4-CARBOXYLIC ACID HYDROXAMIDES | PFIZER PROD INC (US) | 2003-05-02 | — | — | EP | disclosed |
| US-6288246-B1 | REACTION OF HYDROXYLAMINE WITH ALKYLSILYL HALIDE, HYDROLYSIS WITH ACID | PFIZER INC | 2001-09-11 | — | — | US | disclosed |
| EP-1070058-A1 | (4-ARYLSULFONYLAMINO)-TETRAHYDROPYRAN-4-CARBOXYLIC ACID HYDROXAMIDES | Pfizer Products Inc. (US) | 2001-01-24 | — | — | EP | disclosed |
| US-6087392-A | A METALLOPROTEINASE INHIBITORS FOR INHIBITING MAMMALIAN REPROLYSIN | PFIZER INC. (US) | 2000-07-11 | — | — | US | disclosed |
| WO-1999052889-A1 | (4-ARYLSULFONYLAMINO)-TETRAHYDROPYRAN-4-CARBOXYLIC ACID HYDROXAMIDES | PFIZER PRODUCTS INC. (US) | 1999-10-21 | — | — | WO | disclosed |
| EP-0949244-A2 | Process for preparing hydroxamic acids | Pfizer Products Inc. (US) | 1999-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075340-A1 | Triazolotriazine compounds and uses thereof | MET, TPMT, RET | MMP1 3991/4885MMP13 3534/4885MMP2 2374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.